Skip to main content

Zantac Lawsuits: Attorneys Appointed For Leadership Roles

Zantac Lawsuits: Attorneys Appointed For Leadership Roles

Zantac Lawsuits: Attorneys Appointed For Leadership Roles

Introduction

The U.S. District Judge Robin L. Rosenberg, presiding over all federal Zantac lawsuits, appointed two small groups of attorneys to serve in leadership roles.

Zantac (ranitidine hydrochloride) is an antacid and an H2 (histamine-2) receptor blocker used for treating and preventing ulcers in the duodenum, stomach, and intestines. It is also used for treating erosive esophagitis, heartburn, gastroesophageal reflux disease-GERD, Zollinger-Ellison syndrome. In 1983, Glaxo Holdings Ltd, a company which is a part of GlaxoSmithKline PLC, received approval from the FDA to sell Zantac in the U.S. However, owing to patent expiry in 1987 in the United States, Glaxo had to face stiff competition by the generic alternatives launched immediately by competitors. Since 2017, the OTC version of Zantac was marketed by Sanofi in the United States and Canada. In 2004, Pfizer gained FDA approval to sell the Zantac OTC in the United States.

According to the pretrial order issued on February 24, Judge Rosenberg appointed four attorneys to an Initial Census Team and four other attorneys to a Practices and Procedures Team.

The Initial Census Team will assist to outline the process for surveying the number of filed Zantac claims and unfiled cases that attorneys nationwide are continuing to investigate. This will help the Court gauge the size of the litigation and the best way to manage the pretrial proceedings.

The duties of the Practices and Procedures Team, as described in a pretrial order issued on February 20, include the creation of an early dialog regarding the content and timing of procedural orders that may be helpful in the Zantac litigation.

An initial status conference with the presiding judge is scheduled for March 20, during which the appointed attorneys will meet with the Court for the first time. A larger group of Zantac injury attorneys will be appointed around the time of this conference, who will take certain actions that benefit all plaintiffs and argue motions before the Court.

Comments

Restricted HTML

  • Allowed HTML tags: <a href hreflang> <em> <strong> <cite> <blockquote cite> <code> <ul type> <ol start type> <li> <dl> <dt> <dd> <h2 id> <h3 id> <h4 id> <h5 id> <h6 id>
  • Lines and paragraphs break automatically.
  • Web page addresses and email addresses turn into links automatically.

Latest News

Walgreens Settles Federal Opioid Case for $300 Million

Categories: Opioids

Walgreens has agreed to pay $300 million to settle allegations by U.S. prosecutors that it unlawfully filled millions of invalid prescriptions for opioids and other controlled substances.

The U.S. Department of Justice announced on Monday…

Study: Opioid Use in Pregnancy May Shrink Newborn Brains

Categories: Opioids

New research from Children’s National Hospital in Washington, D.C., reveals that infants exposed to opioids in the womb have significantly smaller brain volumes than…

Suboxone Tooth Loss Lawsuits Reviewed at MDL Meeting

Categories: Opioids

The U.S. District Judge overseeing the federal Suboxone tooth decay multidistrict litigation (MDL) is scheduled to meet with attorneys tomorrow to assess the progress of pretrial proceedings and strategize on resolving over 11,000 product…

✍️ Outsource Smarter. Try LPO Free – No Catch.                
Get 2 DLs + 2 Legal Docs – Fully Customized, Free!

Only 15 Firms Accepted – Offer Ends May 31!